IDEXX Laboratories to launch IDEXX Coag Dx™ Analyzer [Trade]
Critical coagulation results in seconds bring IDEXX VetLab® Suite in-house capabilities in line with reference laboratories

Westbrook, Maine, April 26, 2007—IDEXX Laboratories, Inc. (NASDAQ:IDXX), announces the planned launch of the IDEXX Coag Dx™ Analyzer that will enable veterinarians to detect clotting disorders and provide vital information for patients that require critical care and emergency and surgical procedures. This analyzer, the newest member of the IDEXX VetLab® Suite, will deliver results in seconds for fresh and citrated whole blood prothrombin time (PT) and activated partial thromboplastin time (APTT). Identification of coagulation problems is critical before surgery is performed, and in the diagnosis and treatment of animals suspected of having a bleeding disorder. The IDEXX Coag Dx Analyzer is slated to launch in the fourth quarter of 2007.

The IDEXX Coag Dx will be an integral part of the IDEXX VetLab Suite of analyzers, the in-clinic laboratory that delivers comprehensive, in-depth diagnostics, flexibility in testing and efficiencies that minimize staff time and effort. Results are simply and seamlessly integrated for hematology, chemistry, electrolytes, endocrinology, urinalysis, blood gas and, soon, coagulation, through the IDEXX VetLab® Station, as well as archiving and easy access to historical results for identifying and graphically reporting trends.

“The IDEXX Coag Dx Analyzer will connect to the IDEXX VetLab Suite, allowing coagulation results to appear along with the rest of a patient’s results in one integrated report,” said Michael Williams, PhD, IDEXX VetLab Corporate Vice President. “The addition of the Coag Dx Analyzer to the IDEXX VetLab Suite will enable IDEXX to offer veterinarians the most comprehensive point-of-care diagnostic solution, rivaling reference laboratory capabilities for basic blood profiles and emergency and critical care.”

IDEXX will also launch Coag Dx™ cartridges in late May 2007 through a partnership with International Technidyne Corporation (ITC). These cartridges will be compatible with the Synbiotics SCA2000™ as well as the IDEXX Coag Dx™ Analyzer.

For more information about the IDEXX Coag Dx Analyzer or the cartridges, please contact IDEXX at 1-207-556-4504, 1-800-548-6733 ext. 64504, or visit idexx.com/vetlab.

About the IDEXX VetLab Suite
The IDEXX VetLab suite is a highly integrated set of veterinary analyzers that provide a fast and flexible result on a patient’s blood and urine within minutes of the pet visit. Diagnostic capability of the Suite includes clinical chemistry, electrolytes, hematology with five part differential, endocrinology, blood gases, coagulation and urinalysis. The IDEXX VetLab Station, which serves as an information system for this in-house laboratory, integrates results from all the analyzers and IDEXX SNAP point-of-care tests into a single, comprehensive and easy-to-use patient report, and stores this information into its database for easy future reference and historical results trending capability.

About IDEXX Laboratories
IDEXX Laboratories, Inc. is a leader in companion animal health, serving practicing veterinarians around the world with innovative, technology-based offerings, including a broad range of diagnostic products and services, practice management systems and pharmaceuticals. IDEXX products enhance the ability of veterinarians to provide advanced medical care and to build more economically successful practices. IDEXX is also a worldwide leader in providing diagnostic tests and information for the production animal industry and tests for the quality and safety of water and milk. Headquartered in Westbrook, Maine, IDEXX Laboratories employs more than 4,000 people and offers products to customers in over 100 countries.

About ITC
International Technidyne Corporation (ITC), a subsidiary of Thoratec Corporation, is a world leader in the fields of hemostasis management and point-of-care testing with over 37 years of knowledge and experience. ITC develops, manufactures and markets products in six distinct categories: HEMOCHRON® point-of-care coagulation instruments and reagents; IRMA TRUpoint® Blood Analysis System for blood gas and electrolyte testing; AVOXimeter® provides rapid, accurate oximetry and co-oximetry assessment; skin incision products including tenderfoot®, Tenderlett® and Surgicutt®; Hgb Pro Professional Hemoglobin Testing System®; and the ProTime® Microcoagulation System for prothrombin time patient self-testing and for professional use.

Note Regarding Forward-Looking Statements
This press release contains statements about the Company’s business prospects and estimates of the Company’s financial results for future periods that are forward-looking statements as defined in the Private Securities Litigation Reform Act of 1995. These statements are based on management's expectations of future events as of the date of this press release, and the Company assumes no obligation to update any forward-looking statements as a result of new information or future events or developments. Actual results could differ materially from management’s expectations. Factors that could cause or contribute to such differences include the following: the Company’s ability to develop, manufacture, introduce and market new products and enhancements to existing products; the Company’s ability to integrate and operate acquired businesses; the effect of government regulation on the Company’s business, including government decisions about whether and when to approve the sale of the Company’s products and decisions regarding labeling, manufacturing and marketing of products; disruptions, shortages or pricing changes that affect the Company’s purchases of products and materials from third parties, including from sole source suppliers; the impact of distributor purchasing decisions on sales of our products that are sold through distribution; changes or trends in veterinary medicine that affect the rate of use of the Company’s products and services by veterinarians; the Company’s ability to obtain and maintain patent and other intellectual property protection for its products, successfully enforce its intellectual property rights and defend itself against third party claims against the Company; the effects of government regulatory decisions, customer demand, pricing and other factors on the realizability of the Company’s inventories; the Company’s ability to manufacture complex biologic products; the effects of operations outside the U.S., including from currency fluctuations, different regulatory, political and economic conditions, and different market conditions; and the loss of key employees. A further description of these and other factors can be found in the Company's Annual Report on Form 10-K for the year ended December 31, 2006 (1.5 MB), in the section captioned "Risk Factors."

This symbol indicates PDF-formatted materials. To view, you may need to download a free copy of Adobe^® Reader^® software.